A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines

Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists. New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry 2008-03, Vol.16 (6), p.2741-2752
Hauptverfasser: van Veldhoven, Jacobus P.D., Chang, Lisa C.W., von Frijtag Drabbe Künzel, Jacobien K., Mulder-Krieger, Thea, Struensee-Link, Regina, Beukers, Margot W., Brussee, Johannes, IJzerman, Adriaan P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2752
container_issue 6
container_start_page 2741
container_title Bioorganic & medicinal chemistry
container_volume 16
creator van Veldhoven, Jacobus P.D.
Chang, Lisa C.W.
von Frijtag Drabbe Künzel, Jacobien K.
Mulder-Krieger, Thea
Struensee-Link, Regina
Beukers, Margot W.
Brussee, Johannes
IJzerman, Adriaan P.
description Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists. New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A 1 receptors, although affinity for the adenosine A 2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A 1 receptor-selective compounds were 5 (LUF6048), 27 (LUF6040) and 53 (LUF6056) with K i values of 8.1, 1.2 and 5.7 nM, respectively.
doi_str_mv 10.1016/j.bmc.2008.01.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70452361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S096808960800014X</els_id><sourcerecordid>70452361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-c091bbb796c46be9f820f042dbbec7fdd235d3c753517fca62060e4abcbbaf083</originalsourceid><addsrcrecordid>eNp9kE1rFTEUhkNR2mv1B7iRbHQ315NkJjOjq1JsKxTctOuQj5OSy53kmmSU_ntT7kV3wgtn87wvh4eQ9wy2DJj8vNuaxW45wLQF1iLOyIb1su-EmNkrsoFZTh1Ms7wgb0rZAQDvZ3ZOLtjEh6kX84aoKxrxN33CiFnXkCJNnmqHMZUQkWa0eKgpUx2rfkoxlFq-0JucFupCR2uiNYeymlJDXSs6qpcQ0-E5hyW4NlDektde7wu-O91L8njz7eH6rrv_cfv9-uq-s2JitbMwM2PMOEvbS4Oznzh46LkzBu3oneNicMKOgxjY6K2WHCRgr401RnuYxCX5dNw95PRzxVLVEorF_V5HTGtRI_QDF5I1kB1Bm1MpGb06tGd1flYM1ItVtVPNqnqxqoC1iNb5cBpfzYLuX-OksQEfT4AuVu991tGG8pfjwLmEiTfu65HDpuJXwKyKDRgtutBMV-VS-M8bfwAQEZbV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70452361</pqid></control><display><type>article</type><title>A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>van Veldhoven, Jacobus P.D. ; Chang, Lisa C.W. ; von Frijtag Drabbe Künzel, Jacobien K. ; Mulder-Krieger, Thea ; Struensee-Link, Regina ; Beukers, Margot W. ; Brussee, Johannes ; IJzerman, Adriaan P.</creator><creatorcontrib>van Veldhoven, Jacobus P.D. ; Chang, Lisa C.W. ; von Frijtag Drabbe Künzel, Jacobien K. ; Mulder-Krieger, Thea ; Struensee-Link, Regina ; Beukers, Margot W. ; Brussee, Johannes ; IJzerman, Adriaan P.</creatorcontrib><description>Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists. New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A 1 receptors, although affinity for the adenosine A 2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A 1 receptor-selective compounds were 5 (LUF6048), 27 (LUF6040) and 53 (LUF6056) with K i values of 8.1, 1.2 and 5.7 nM, respectively.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2008.01.013</identifier><identifier>PMID: 18258439</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adenosine ; Adenosine A 1 receptor ; Amines ; Biological and medical sciences ; Cyanopyrimidines ; Cyclic AMP ; Humans ; Inverse agonist ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Purinergic P1 Receptor Antagonists ; Pyrimidines - chemistry ; Pyrimidines - pharmacology ; Receptor, Adenosine A1 ; Receptor, Adenosine A2A ; Structure-Activity Relationship</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2008-03, Vol.16 (6), p.2741-2752</ispartof><rights>2008 Elsevier Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-c091bbb796c46be9f820f042dbbec7fdd235d3c753517fca62060e4abcbbaf083</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bmc.2008.01.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20226082$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18258439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Veldhoven, Jacobus P.D.</creatorcontrib><creatorcontrib>Chang, Lisa C.W.</creatorcontrib><creatorcontrib>von Frijtag Drabbe Künzel, Jacobien K.</creatorcontrib><creatorcontrib>Mulder-Krieger, Thea</creatorcontrib><creatorcontrib>Struensee-Link, Regina</creatorcontrib><creatorcontrib>Beukers, Margot W.</creatorcontrib><creatorcontrib>Brussee, Johannes</creatorcontrib><creatorcontrib>IJzerman, Adriaan P.</creatorcontrib><title>A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists. New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A 1 receptors, although affinity for the adenosine A 2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A 1 receptor-selective compounds were 5 (LUF6048), 27 (LUF6040) and 53 (LUF6056) with K i values of 8.1, 1.2 and 5.7 nM, respectively.</description><subject>Adenosine</subject><subject>Adenosine A 1 receptor</subject><subject>Amines</subject><subject>Biological and medical sciences</subject><subject>Cyanopyrimidines</subject><subject>Cyclic AMP</subject><subject>Humans</subject><subject>Inverse agonist</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Purinergic P1 Receptor Antagonists</subject><subject>Pyrimidines - chemistry</subject><subject>Pyrimidines - pharmacology</subject><subject>Receptor, Adenosine A1</subject><subject>Receptor, Adenosine A2A</subject><subject>Structure-Activity Relationship</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rFTEUhkNR2mv1B7iRbHQ315NkJjOjq1JsKxTctOuQj5OSy53kmmSU_ntT7kV3wgtn87wvh4eQ9wy2DJj8vNuaxW45wLQF1iLOyIb1su-EmNkrsoFZTh1Ms7wgb0rZAQDvZ3ZOLtjEh6kX84aoKxrxN33CiFnXkCJNnmqHMZUQkWa0eKgpUx2rfkoxlFq-0JucFupCR2uiNYeymlJDXSs6qpcQ0-E5hyW4NlDektde7wu-O91L8njz7eH6rrv_cfv9-uq-s2JitbMwM2PMOEvbS4Oznzh46LkzBu3oneNicMKOgxjY6K2WHCRgr401RnuYxCX5dNw95PRzxVLVEorF_V5HTGtRI_QDF5I1kB1Bm1MpGb06tGd1flYM1ItVtVPNqnqxqoC1iNb5cBpfzYLuX-OksQEfT4AuVu991tGG8pfjwLmEiTfu65HDpuJXwKyKDRgtutBMV-VS-M8bfwAQEZbV</recordid><startdate>20080315</startdate><enddate>20080315</enddate><creator>van Veldhoven, Jacobus P.D.</creator><creator>Chang, Lisa C.W.</creator><creator>von Frijtag Drabbe Künzel, Jacobien K.</creator><creator>Mulder-Krieger, Thea</creator><creator>Struensee-Link, Regina</creator><creator>Beukers, Margot W.</creator><creator>Brussee, Johannes</creator><creator>IJzerman, Adriaan P.</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080315</creationdate><title>A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines</title><author>van Veldhoven, Jacobus P.D. ; Chang, Lisa C.W. ; von Frijtag Drabbe Künzel, Jacobien K. ; Mulder-Krieger, Thea ; Struensee-Link, Regina ; Beukers, Margot W. ; Brussee, Johannes ; IJzerman, Adriaan P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-c091bbb796c46be9f820f042dbbec7fdd235d3c753517fca62060e4abcbbaf083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adenosine</topic><topic>Adenosine A 1 receptor</topic><topic>Amines</topic><topic>Biological and medical sciences</topic><topic>Cyanopyrimidines</topic><topic>Cyclic AMP</topic><topic>Humans</topic><topic>Inverse agonist</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Purinergic P1 Receptor Antagonists</topic><topic>Pyrimidines - chemistry</topic><topic>Pyrimidines - pharmacology</topic><topic>Receptor, Adenosine A1</topic><topic>Receptor, Adenosine A2A</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Veldhoven, Jacobus P.D.</creatorcontrib><creatorcontrib>Chang, Lisa C.W.</creatorcontrib><creatorcontrib>von Frijtag Drabbe Künzel, Jacobien K.</creatorcontrib><creatorcontrib>Mulder-Krieger, Thea</creatorcontrib><creatorcontrib>Struensee-Link, Regina</creatorcontrib><creatorcontrib>Beukers, Margot W.</creatorcontrib><creatorcontrib>Brussee, Johannes</creatorcontrib><creatorcontrib>IJzerman, Adriaan P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Veldhoven, Jacobus P.D.</au><au>Chang, Lisa C.W.</au><au>von Frijtag Drabbe Künzel, Jacobien K.</au><au>Mulder-Krieger, Thea</au><au>Struensee-Link, Regina</au><au>Beukers, Margot W.</au><au>Brussee, Johannes</au><au>IJzerman, Adriaan P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2008-03-15</date><risdate>2008</risdate><volume>16</volume><issue>6</issue><spage>2741</spage><epage>2752</epage><pages>2741-2752</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>Di- and trisubstituted aminopyrimidines as adenosine receptor antagonists. New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A 1 receptors, although affinity for the adenosine A 2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A 1 receptor-selective compounds were 5 (LUF6048), 27 (LUF6040) and 53 (LUF6056) with K i values of 8.1, 1.2 and 5.7 nM, respectively.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>18258439</pmid><doi>10.1016/j.bmc.2008.01.013</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2008-03, Vol.16 (6), p.2741-2752
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_70452361
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adenosine
Adenosine A 1 receptor
Amines
Biological and medical sciences
Cyanopyrimidines
Cyclic AMP
Humans
Inverse agonist
Medical sciences
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems
Pharmacology. Drug treatments
Purinergic P1 Receptor Antagonists
Pyrimidines - chemistry
Pyrimidines - pharmacology
Receptor, Adenosine A1
Receptor, Adenosine A2A
Structure-Activity Relationship
title A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T22%3A27%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20generation%20of%20adenosine%20receptor%20antagonists:%20From%20di-%20to%20trisubstituted%20aminopyrimidines&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=van%20Veldhoven,%20Jacobus%20P.D.&rft.date=2008-03-15&rft.volume=16&rft.issue=6&rft.spage=2741&rft.epage=2752&rft.pages=2741-2752&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2008.01.013&rft_dat=%3Cproquest_cross%3E70452361%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70452361&rft_id=info:pmid/18258439&rft_els_id=S096808960800014X&rfr_iscdi=true